A mouse model to investigate the impact of testosterone therapy on reproduction in transgender men

Published on Oct 2, 2019in Human Reproduction5.733
· DOI :10.1093/HUMREP/DEZ177
Hadrian M Kinnear4
Estimated H-index: 4
(UM: University of Michigan),
E.S. Constance2
Estimated H-index: 2
(UM: University of Michigan)
+ 4 AuthorsMolly B. Moravek15
Estimated H-index: 15
(UM: University of Michigan)
Sources
Abstract
STUDY QUESTION: Can mice serve as a translational model to investigate the reproductive effects of testosterone (T) therapy commonly used by transgender men? SUMMARY ANSWER: T enanthate subcutaneous injections at 0.45 mg twice weekly can be used in the postpubertal C57BL/6N female mouse to investigate the reproductive effects of T therapy given to transgender men. WHAT IS KNOWN ALREADY: Most models of T treatment in female mice involve prenatal or prepubertal administration, which are not applicable to transgender men who often begin T therapy after puberty. Studies that have looked at the impact of postpubertal T treatment in female mice have generally not investigated reproductive outcomes. STUDY DESIGN, SIZE, DURATION: A total of 20 C57BL/6N female mice were used for this study. Study groups (n = 5 mice per group) included sesame oil vehicle controls and three doses of T enanthate (0.225, 0.45 and 0.90 mg). Mice were injected subcutaneously twice weekly for 6 weeks. PARTICIPANTS/MATERIALS, SETTING, METHODS: Daily vaginal cytology was performed prior to initiation of treatment to confirm that all mice were cycling. At 8-9 weeks of age, therapy with subcutaneous T enanthate (0.225, 0.45 or 0.90 mg) or the vehicle control was begun. T therapy continued for 6 weeks, at which point mice were sacrificed and compared to control mice sacrificed during diestrus/metestrus. Data collected included daily vaginal cytology, weekly and terminal reproductive hormone levels, terminal body/organ weights/measurements, ovarian follicular distribution/morphology and corpora lutea counts. MAIN RESULTS AND THE ROLE OF CHANCE: Of the mice treated with 0.90 mg T enanthate, two of five mice experienced vaginal prolapse, so this group was excluded from further analysis. T enanthate administration twice weekly at 0.225 or 0.45 mg resulted in cessation of cyclicity and persistent diestrus. One of five mice at the 0.225-mg dose resumed cycling after 2.5 weeks of T therapy. As compared to controls, T-treated mice had sustained elevated T levels and luteinizing hormone (LH) suppression in the terminal blood sample. T-treated mice demonstrated increases in clitoral area and atretic cyst-like late antral follicles (0.45 mg only) as compared to controls. No reduction in primordial, primary, secondary or total antral follicle counts was detected in T-treated mice as compared to controls, and T-treated mice demonstrated an absence of corpora lutea. LIMITATIONS, REASONS FOR CAUTION: Mouse models can provide us with relevant key findings for further exploration but may not perfectly mirror human reproductive physiology. WIDER IMPLICATIONS OF THE FINDINGS: To our knowledge, this report describes the first mouse model mimicking T therapy given to transgender men that facilitates analysis of reproductive changes. This model allows for future studies comparing duration and reversibility of T-induced changes, on the reproductive and other systems. It supports a role for T therapy in suppressing the hypothalamic-pituitary-gonadal axis in adult female mice as evidenced by LH suppression, persistent diestrus and absence of corpora lutea. The increase in atretic cyst-like late antral follicles aligns with the increased prevalence of polycystic ovary morphology seen in case series of transgender men treated with T therapy. The results also suggest that T therapy does not deplete the ovarian reserve. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the American Society for Reproductive Medicine/Society of Reproductive Endocrinology and Infertility Grant and NIH R01-HD098233 to M.B.M. and University of Michigan Office of Research funding (U058227). H.M.K. was supported by the Career Training in Reproductive Biology and Medical Scientist Training Program T32 NIH Training Grants (T32-HD079342, T32-GM07863) as well as the Cellular and Molecular Biology Program. The University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core is supported by the Eunice Kennedy Shriver NICHD/NIH (NCTRI) Grant P50-HD28934. E.E.M. consults for Allergan. No other authors have competing interests.
Download
📖 Papers frequently viewed together
2 Citations
176 Citations
References38
Newest
#1Frances Grimstad (KU: University of Kansas)H-Index: 8
#2Kylie Fowler (Children's Hospitals and Clinics of Minnesota)H-Index: 2
Last. Meredith Gray (KU: University of Kansas)H-Index: 3
view all 8 authors...
Background As part of transition, transmasculine persons often use testosterone gender-affirming hormone therapy; however, there is limited data on its long-term effects. The impact of exogenous testosterone on uterine pathology remains unclear. While testosterone achieves amenorrhea in the majority of this population, persistence of abnormal uterine bleeding can be difficult to manage. Excess androgens in cisgender females are associated with pathologic uterine processes such as polycystic ovar...
28 CitationsSource
#1Laura G. Goetz (Yale University)H-Index: 5
#2Ramanaiah Mamillapalli (Yale University)H-Index: 19
Last. Hugh S. Taylor (Yale University)H-Index: 88
view all 6 authors...
Cross-sex hormone therapy (XHT) is widely used by transgender people to alter secondary sex characteristics to match their desired gender presentation. Here, we investigate the long-term effects of XHT on bone health using a murine model. Female mice underwent ovariectomy at either 6 or 10 wk and began weekly testosterone or vehicle injections. Dual-energy X-ray absorptiometry (DXA) was performed (20 wk) to measure bone mineral density (BMD), and microcomputed tomography was performed to compare...
7 CitationsSource
#1Mirte R. Caanen (VUmc: VU University Medical Center)H-Index: 6
#2Nienke E Schouten (VUmc: VU University Medical Center)H-Index: 1
Last. Cornelis B. Lambalk (VUmc: VU University Medical Center)H-Index: 62
view all 10 authors...
STUDY QUESTION Does long-term exogenous testosterone administration result in polycystic ovarian morphology (PCOM), determined by (3D) transvaginal ultrasound (TVU) in female-to-male transsexuals (FtMs). SUMMARY ANSWER Long-term exogenous testosterone administration in FtMs does not result in PCOM determined by (3D) TVU. WHAT IS KNOWN ALREADY The role of androgens in the pathophysiology of polycystic ovary syndrome (PCOS) is still unclear. From animal studies, intra-ovarian androgens have been s...
18 CitationsSource
#1Yaping MaH-Index: 3
#2Stanley AndrisseH-Index: 4
Last. Sheng Wu (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 18
view all 10 authors...
Androgen and its receptor (AR) plays a critical role in reproductive function, under both physiological and pathophysiological conditions. Female AR global knockout mice are sub-fertile due to both neuroendocrine and ovarian defects. Female offspring from prenatally androgenized heterozygous AR pregnant mice showed rescued estrous cyclicity and fertility. Ar is expressed in granulosa cells, theca interstitial cells, and oocytes in the ovary. We created mice with theca-specific deletion of Ar (Th...
35 CitationsSource
#1Siri Atma W. Greeley (U of C: University of Chicago)H-Index: 24
#2Mark C. Zielinski (U of C: University of Chicago)H-Index: 12
Last. Manami Hara (U of C: University of Chicago)H-Index: 33
view all 11 authors...
Context: The most common genetic cause of permanent neonatal diabetes mellitus is activating mutations in KCNJ11, which can usually be treated using oral sulfonylureas (SU) instead of insulin injections, although some mutations are SU unresponsive. Here, we provide the first report of the pancreatic islet endocrine cell composition and area in a patient with an SU-unresponsive KCNJ11 mutation (p.G334D), in comparison to age-matched controls. Case Description: Pancreatic autopsy tissue sections f...
31 CitationsSource
#1Giuseppe Loverro (University of Bari)H-Index: 32
#2Leonardo Resta (University of Bari)H-Index: 26
Last. Salvatore Andrea Mastrolia (University of Bari)H-Index: 14
view all 7 authors...
Abstract Objective Female-to-male transition remains a specific clinical indication for long-term testosterone administration. There is a limited number of studies dealing with the effect of androgen treatment on their female receptive targets (mainly breast and uterus) and the knowledge in this field is scarce and, sometimes, contradictory. Materials and Methods We performed a prospective study including 12 patients aged between 20 years and 32 years, with a diagnosis of gender dysphoria, treat...
32 CitationsSource
#1Chloë De Roo (Ghent University Hospital)H-Index: 2
#2Kelly Tilleman (Ghent University Hospital)H-Index: 12
Last. Petra De Sutter (Ghent University Hospital)H-Index: 49
view all 4 authors...
AbstractHormonal and surgical treatments for transgender people have a devastating effect on the possibility for these patients to reproduce. Additionally, transgender people tend to start sex reassignment treatment at a young age, when reproductive wishes are not yet clearly defined nor fulfilled. The most recent Standards of Care of the World Professional Association for Transgender Health recommend clearly informing patients regarding their future reproductive options prior to initiation of t...
90 CitationsSource
#1Mei YangH-Index: 1
#2Jianhua LiH-Index: 1
Last. Shuiwen ZhangH-Index: 1
view all 4 authors...
Abstract Androgens have essential roles in the regulation of follicular development and female fertility. Androgen excess is the leading defect in polycystic ovary syndrome (PCOS) patients and involved in the ovarian dysfunction. The aim of this study was to elucidate the regarding regulatory role of androgen in the follicular development of female mouse. Immunohistochemical staining and Western blot analyses were performed to detect androgen receptor (AR) and Connexin 43 (Cx43) expression in ov...
11 CitationsSource
#1Michelle C. Cora (NIH: National Institutes of Health)H-Index: 7
#2Linda Kooistra (Charles River Laboratories)H-Index: 5
Last. Greg Travlos (NIH: National Institutes of Health)H-Index: 14
view all 3 authors...
Microscopic evaluation of the types of cells present in vaginal smears has long been used to document the stages of the estrous cycle in laboratory rats and mice and as an index of the functional status of the hypothalamic–pituitary–ovarian axis. The estrous cycle is generally divided into the four stages of proestrus, estrus, metestrus, and diestrus. On cytological evaluation, these stages are defined by the absence, presence, or proportion of 4 basic cell types as well as by the cell density a...
240 CitationsSource
#1Alexis Light (UCSF: University of California, San Francisco)H-Index: 7
#2Juno Obedin-Maliver (UCSF: University of California, San Francisco)H-Index: 14
Last. Jennifer L. KernsH-Index: 13
view all 4 authors...
Author(s): Light, Alexis D; Obedin-Maliver, Juno; Sevelius, Jae M; Kerns, Jennifer L | Abstract: OBJECTIVE: To conduct a cross-sectional study of transgender men who had been pregnant and delivered after transitioning from female-to-male gender to help guide practice and further investigation. MATERIALS AND METHODS: We administered a web-based survey from March to December 2013 to inquire about demographics, hormone use, fertility, pregnancy experience, and birth outcomes. Participants were not ...
237 CitationsSource
Cited By7
Newest
Purpose of review null To synthesize recent literature to better understand parenting desires and challenges of transgender individuals as well as the impact of gender-affirming care on reproductive potential. null Recent findings null Survey studies of transgender and nonbinary individuals demonstrate significant parenting interest, yet uptake in fertility preservation services remains low with potential for decisional regret. Masculinizing hormones have demonstrated variable effects on follicu...
Source
#1Hadrian M Kinnear (UM: University of Michigan)H-Index: 4
#2Prianka H Hashim (UM: University of Michigan)
Last. Molly B. Moravek (UM: University of Michigan)H-Index: 15
view all 10 authors...
Objective To establish if the cessation of testosterone (T) therapy reverses T-induced acyclicity in a transgender mouse model that allows for well-defined T cessation timing. Design Experimental laboratory study using a mouse model. Setting University-based basic science research laboratory. Animals A total of 10 C57BL/6NHsd female mice were used in this study. Intervention(s) Postpubertal C57BL/6NHsd female mice were subcutaneously implanted with T enanthate (n = 5 mice) or placebo (n = 5 mice...
Source
#1Lourdes A Esparza (UCSD: University of California, San Diego)H-Index: 3
#1Lourdes A. Esparza (UCSD: University of California, San Diego)H-Index: 7
Last. Alexander S. Kauffman (UCSD: University of California, San Diego)H-Index: 37
view all 4 authors...
Androgens can affect the reproductive axis of both sexes. In healthy women, as in men, elevated exogenous androgens decrease gonad function and lower gonadotropin levels; such circumstances occur with anabolic steroid abuse or in transgender men (genetic XX individuals) taking androgen supplements. The neuroendocrine mechanisms by which endogenous or exogenous androgens regulate gonadotropin release, including aspects of pulsatile luteinizing hormone (LH) secretion, remain unknown. Because anima...
Source
#1Chantal Bartels (University of Connecticut Health Center)H-Index: 3
#2Tracy F. Uliasz (University of Connecticut Health Center)H-Index: 16
Last. Lisa M. Mehlmann (University of Connecticut Health Center)H-Index: 25
view all 4 authors...
STUDY QUESTION Does testosterone use in females affect reproductive potential, particularly with regard to the production of fertilizable gametes? SUMMARY ANSWER Testosterone (T) injections given to post-pubertal female mice caused virilization and although the ovaries were smaller than controls they were still responsive and produced fertilizable eggs when superovulated. WHAT IS KNOWN ALREADY Studies to examine the effects of testosterone on reproductive potential in transgender males are lacki...
2 CitationsSource
#1Viji Sundaram (UCSF: University of California, San Francisco)H-Index: 2
#2Evelyn Mok-Lin (UCSF: University of California, San Francisco)H-Index: 8
This review aims to update readers on recent evidence in order to counsel and guide clinical management of individuals with gender dysphoria seeking fertility preservation (FP). Relevant topics include a discussion of the consistent desire for children in transgender people despite a low utilization rate of FP services, animal models, and human histology depicting the effect of gender-affirming treatment (GAT) on the gonads, varied time for resumption of menses, and start of ovarian stimulation ...
Source
#1Chantal Bartels (University of Connecticut Health Center)H-Index: 3
#2Tracy F. Uliasz (University of Connecticut Health Center)H-Index: 16
Last. Lisa M. Mehlmann (University of Connecticut Health Center)H-Index: 25
view all 4 authors...
STUDY QUESTION: Does testosterone use in females affect reproductive potential, particularly with regard to the production of fertilizable gametes? SUMMARY ANSWER: Testosterone cypionate injections given to post-pubertal female mice caused virilization and ovaries were smaller than control ovaries, but ovaries were still responsive to hormonal stimulation and produced fertilizable eggs when superovulated. WHAT IS KNOWN ALREADY: Studies to examine the effects of testosterone on reproductive poten...
Source
#1Molly B. Moravek (UM: University of Michigan)H-Index: 15
#2Hadrian M Kinnear (UM: University of Michigan)H-Index: 4
Last. John F. Randolph (UM: University of Michigan)H-Index: 49
view all 7 authors...
Studies show that a subset of transgender men desire children; however, there is a paucity of literature on the effect of gender-affirming testosterone therapy on reproductive function. In this manuscript, we will review the process of gender-affirming hormone therapy for transgender men and what is known about ovarian and uterine consequences of testosterone exposure in transgender men; draw parallels with existing animal models of androgen exposure; summarize the existing literature on parenti...
8 CitationsSource